Je was op zoek naar: clinical development program consists (Engels - Estisch)

mitotane has not been studied in a comprehensive clinical development program.
mitotaani ei ole ulatusliku kliinilise uuringuprogrammiga uuritud.

clinical efficacy mitotane has not been studied in a comprehensive clinical development program.
kliiniline tõhusus mitotaani ei ole ulatusliku kliinilise uuringuprogrammiga uuritud.

the clinical development program was composed by 5 studies provided in the following table:
10/ 20 Ü, 20/ 40 Ü, 30/ 60 Ü botox 30/ 60 Ü intramuskulaarselt

adverse reactions observed in the clinical development of numient
numient’i kliinilise väljatöötamise käigus täheldatud kõrvaltoimed

no cases of overdose after cutaneous use of mirvaso were reported during the clinical development program.
kliinilise arendamise programmi käigus ei teatatud ühestki mirvaso kutaanse kasutamise järgsest üleannustamisest.

during clinical development dosages of 10mg/ day have been used.
kliiniliste uuringute ajal kasutati annust 10 mg/ päevas.

the safety profile of spedra is based on 2436 subjects exposed to avanafil during the clinical development program.
spedra ohutusprofiil põhineb kliinilises arendusprogrammis avanafiiliga ravitud 2436 uuringuosalise andmetel.

no case of overdose with krystexxa has been reported during clinical development.
kliinilise arenduse käigus ei ole krystexxa üleannustamisest teatatud.

the clinical development of duotrav included both patients naive and on therapy.
duotrav’i kliiniline arendamine hõlmab nii eelneva ravita kui ka ravi saanud patsiente.

the phase iii clinical development program for kuvan included 2, randomised placebo-controlled studies in patients with pku.
kuvan’i iii faasi kliiniline arendusprogramm sisaldas 2 randomiseeritud ja platseebokontrollitud uuringut pku-ga patsientidel.

the safety of optaflu has been assessed in seven randomized, active controlled clinical trials performed as part of the development program.
optaflu ohutust on hinnatud seitsmes randomiseeritud, aktiivse kontrolliga kliinilises uuringus, mis viidi läbi ühe osana arendusprogrammist.

the description of the development program shall address the choice of materials and processes.
arenduskavas selgitatakse materjalide ja protsesside valikut.

the adverse drug reactions were determined based on data from the apremilast clinical development programme.
kõrvaltoimed määratleti apremilasti kliiniliste uuringute andmete põhjal.

the brimica genuair clinical development programme was conducted in patients with moderate or severe copd.
brimica genuair´i kliiniline arendusprogramm viidi läbi mõõduka või raskekujulise kok-ga patsientidel.

during the pre-licensure clinical development program, a total of 1,737 pregnancies were reported including 870 in women who had received cervarix.
kliinilises registreerimiseelses arendusprogrammis teatati kokku 1737st rasestumistest, sealhulgas 870st naisest, kes olid saanud cervarix`i.

a total of 4,204 patients were treated with taltz in clinical development studies in plaque psoriasis.
taltz’iga raviti kliinilistes uuringutes kokku 4204 naastulise psoriaasiga patsienti.

during clinical development of ilaris in over 2,300 patients, no anaphylactoid or anaphylactic reactions were reported.
kliinilise arenduse ajal ei kirjeldatud rohkem kui 2300 patsiendil anafülaktoidseid või anafülaktilisi reaktsioone.

the hirobriz breezhaler phase iii clinical development programme involved patients with a clinical diagnosis of moderate to severe copd.
hirobriz breezhaler’i iii faasi kliinilises arendusprogrammis osalesid patsiendid, kelle kliiniliseks diagnoosiks oli keskmise raskusega või raske kok.

during clinical development, a total of 362 patients were treated with the concentrate of proteolytic enzymes enriched in bromelain.
kliinilise arendamise käigus raviti bromelaiinis rikastatud proteolüütiliste ensüümide kontsentraadiga kokku 362 patsienti.

during the clinical development program, 3,819 women (vaccine = 1,894 vs. placebo = 1,925) reported at least one pregnancy.
kliinilise arenguprogrammi jooksul teatati vähemalt ühest rasedusest 3819 naisel (vaktsiin = 1894 vs platseebo = 1925).